Search Results

You are looking at 121 - 130 of 858 items for :

  • Refine by Access: All x
Clear All
Full access

Primary Mediastinal B-Cell Lymphoma in Children and Young Adults

Christopher J. Forlenza, Amy Chadburn, and Lisa Giulino-Roth

PET alone. Emerging Biomarkers in PMBCL: Circulating Tumor DNA Given the limited predictive value of FDG-PET in PMBCL, additional biomarkers predictive of response could help to better identify patients at risk for relapse. 11 , 33 Circulating

Full access

NCCN Task Force Report: Molecular Markers in Leukemias and Lymphomas

Jerald P. Radich, Andrew D. Zelenetz, Wing C. Chan, Carlo M. Croce, Myron S. Czuczman, Harry P. Erba, Sandra J. Horning, Jane Houldsworth, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Meir Wetzler, and Jane N. Winter

– 4256 . 37 Press RD Galderisi C Yang R . A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response . Clin Cancer Res 2007 ; 13

Full access

The Role of Myeloid Growth Factors in Acute Leukemia

Martha Wadleigh and Richard M. Stone

SA DiCarlo J Groshek P . Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia . Leukemia 1991 ; 5 : 230 – 238 . 24 Frenette PS

Full access

Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma

Silviya K. Meletath, Dean Pavlick, Tim Brennan, Roy Hamilton, Juliann Chmielecki, Julia A. Elvin, Norma Palma, Jeffrey S. Ross, Vincent A. Miller, Philip J. Stephens, George Snipes, Veena Rajaram, Siraj M. Ali, and Isaac Melguizo-Gavilanes

. arm. However, he experienced disease relapse 4 months after completion of his CCRT, with an MRI revealing new areas of enhancement superior and medial to the left parietal lobe surgical cavity. Advanced DSC (dynamic susceptibility-weighted contrast

Full access

Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Ayman Saad, Marcos de Lima, Sarah Anand, Vijaya Raj Bhatt, Ryan Bookout, George Chen, Daniel Couriel, Antonio Di Stasi, Areej El-Jawahri, Sergio Giralt, Jonathan Gutman, Vincent Ho, Mitchell Horwitz, Joe Hsu, Mark Juckett, Mohamed Kharfan Dabaja, Alison W. Loren, MSCE, Javier Meade, Marco Mielcarek, Jonathan Moreira, Ryotaro Nakamura, Yago Nieto, Julianna Roddy, Gowri Satyanarayana, Mark Schroeder, Carlyn Rose Tan, Dimitrios Tzachanis, Jennifer L. Burns, and Lenora A. Pluchino

HCT. 11 However, disease relapse and long-term complications continue to pose a major threat to HCT survivors. Disease relapse is higher with advanced disease and with the use of nonmyeloablative conditioning regimens. Posttransplant complications are

Full access

Identification of a Novel Fusion Gene, IRF2BP2-RARA, in Acute Promyelocytic Leukemia

C. Cameron Yin, Nitin Jain, Meenakshi Mehrotra, Jianhua Zhagn, Alexei Protopopov, Zhuang Zuo, Naveen Pemmaraju, Courtney DiNardo, Cheryl Hirsch-Ginsberg, Sa A. Wang, L. Jeffrey Medeiros, Lynda Chin, Keyur P. Patel, Farhad Ravandi, Andrew Futreal, and Carlos E. Bueso-Ramos

experienced relapse 2 months after completion of consolidation therapy. She then received salvage therapy with ATRA, arsenic trioxide, and idarubicin, followed by haploidentical bone marrow transplantation. At the time of writing, she was experiencing complete

Full access

The Role of Maintenance Therapy in the Treatment of Multiple Myeloma

Ashraf Z. Badros

orally on days 1 to 4 of a 28-day cycle produced a similar median duration of remission, but significantly fewer patients treated with dexamethasone maintenance responded to repeat melphalan/dexamethasone at relapse relative to those treated with

Full access

Allogeneic Stem Cell Transplantation for Philadelphia Chromosome–Positive Acute Myeloid Leukemia

Vijaya Raj Bhatt, Mojtaba Akhtari, R. Gregory Bociek, Jennifer N. Sanmann, Ji Yuan, Bhavana J. Dave, Warren G. Sanger, Anne Kessinger, and James O. Armitage

.2) translocation, which results in the Ph chromosome, can occur in AML as a de novo chromosomal aberration with or without additional abnormalities or as a therapy-related event. 2 , 9 In de novo cases, it may be present at AML diagnosis or relapse. 1 , 10 , 11

Full access

Symptom Burden, Perceived Control, and Quality of Life Among Patients Living With Multiple Myeloma

Alexandra K. Zaleta, Melissa F. Miller, Julie S. Olson, Eva Y.N. Yuen, Thomas W. LeBlanc, Craig E. Cole, Shauna McManus, and Joanne S. Buzaglo

, or other/multiracial), Hispanic ethnicity, region, annual household income, education (dichotomized as whether the patient graduated from college), and employment status. Participants also reported years since MM diagnosis, history of relapse, history

Full access

Intermittent Versus Continuous Androgen Deprivation Therapy

Celestia S. Higano

therapy for prostate cancer, often called biochemical relapse . These men had no symptoms of cancer, yet were often treated with ADT because of concern for cancer progression. The side effects and toxicities of ADT became more apparent and assumed greater